Pfizer (PFE) reported Q3 FY2024 earnings of $1.06 per share (versus ($0.17) per share in Q3 FY2023), strongly beating analysts’ consensus estimate of $0.61 per share.
The company’s quarterly revenues amounted to $17.702 bln (+31.2% y/y), strongly beating analysts’ consensus estimate of $14.921 bln.
The company also issued raised guidance for FY2024. It now sees EPS of $2.75-$2.95 versus its prior guidance of $2.45-$2.65 and analysts’ consensus estimate of $2.66, and revenues of $61.0-$64.0 bln versus its prior guidance of $59.5-$62.5 bln and analysts’ consensus estimate of $61.13 bln.
PFE rose to $29.49 (+2.18%) in pre-market trading.